Dragon Pharma AOD 9604 – Growth Hormone Fragment
AOD 9604 5 mg by Dragon Pharma is a synthetic peptide fragment derived from the fat-burning region of human growth hormone. This research peptide has gained attention for its potential ability to stimulate lipolysis and support fat metabolism without the broader hormonal effects associated with full growth hormone.
Originally investigated as a treatment for obesity, AOD 9604 is now widely studied in metabolic and body composition research. Athletes and fitness enthusiasts often explore peptides like AOD 9604 as part of cutting protocols aimed at reducing stubborn body fat while maintaining lean mass.
AOD 9604 Composition
AOD 9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone corresponding to the C-terminal amino acid sequence hGH 176-191 with an additional tyrosine residue.
This specific sequence is believed to mimic the lipolytic region of growth hormone responsible for fat metabolism. Unlike full hGH, the peptide does not stimulate IGF-1 production or influence insulin regulation, which is why it is often investigated as a more targeted metabolic compound.
Body Composition and Cutting Research
AOD 9604 is primarily studied for its potential effects on fat metabolism and lipid mobilization. Research suggests that the peptide may support:
- Activation of lipolysis (fat breakdown)
- Reduced formation of new adipose tissue
- Enhanced fat oxidation during calorie restriction
- Preservation of lean muscle during cutting phases
Because AOD 9604 does not act as a stimulant, it does not produce the jittery effects commonly associated with thermogenic fat burners. This makes it an interesting compound for metabolic research related to body composition and fat reduction.
Scientific Research Background
AOD 9604 was originally developed by Metabolic Pharmaceuticals as part of obesity research programs. Preclinical studies demonstrated that the peptide could increase fat oxidation and reduce adipose tissue accumulation in experimental models.
Importantly, the peptide does not appear to influence growth hormone receptors directly. This allows researchers to study the metabolic effects of the growth hormone fat-burning region without triggering broader hormonal activity.
For more information on AOD 9604 and lipid metabolism research, see this PubMed publication discussing growth hormone fragments and fat metabolism.
Dosage (Men)
Important: AOD 9604 is intended for research purposes only.
Typical experimental protocols reference doses ranging from 250–500 mcg per day administered via subcutaneous injection. The 5 mg vial is commonly reconstituted with bacteriostatic water to allow accurate dosing for research applications.
Research cycles typically range between 4 and 12 weeks depending on the study design.
Dosage (Women)
Female research protocols generally begin with lower doses around 250 mcg daily. Because AOD 9604 does not influence androgenic pathways, it has been investigated in both male and female body composition research.
Active Life
AOD 9604 has a short circulating half-life, but its metabolic effects are considered cumulative with consistent daily administration in research settings.
AOD 9604 Side Effects
Clinical and research data suggest that AOD 9604 demonstrates a favorable safety profile when compared to full growth hormone therapy. Reported effects are generally mild and may include minor injection-site irritation or temporary fatigue.
The peptide does not appear to influence blood glucose levels, IGF-1 production, or insulin secretion.
Contraindications / Precautionary Measures
AOD 9604 should not be used by pregnant or nursing women. Individuals with active malignancies or serious metabolic disorders should consult medical professionals before considering peptide research.
Overdosage
No confirmed cases of AOD 9604 overdose have been documented. Exceeding typical research ranges is unlikely to accelerate results and may increase the likelihood of mild side effects.
AOD 9604 Stack / Research Combinations
Within peptide research communities, AOD 9604 is often studied alongside other metabolic and growth hormone-related compounds.
Package Presentation
Dragon Pharma supplies AOD 9604 in sterile 2 mL vials containing 5 mg of lyophilized peptide powder. Lyophilization helps maintain peptide stability prior to reconstitution.
Storage
Store the unopened vial in a cool, dry environment. Refrigeration at 2-8°C is recommended.
After reconstitution, the peptide should remain refrigerated and used within several weeks to maintain stability.
Research Disclaimer
This product is intended for laboratory research and analytical purposes only. It is not approved for human consumption.
